Matching trials
2,411 results
- Endoscopic Therapy of Early Cancer in Barretts Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Endoscopic Therapy of Early Cancer in Barretts Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00217087).
- Endothelial Hyperpolarization in Humans: Complete Statistical AnalysisIndependent statistical analysis of Endothelial Hyperpolarization in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00166166).
- ENDUREIndependent statistical analysis of A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis…
- ENERGIZEIndependent statistical analysis of A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8: primary endpoint results, effect estimate with confidence interval, sample-size…
- ENESTopAn independent statistical analysis of the phase 2 ENESTop trial of nilotinib cessation after sustained MR4.5 in chronic myeloid leukemia, including its single-group design, treatment-free remission endpoint, planned statistical approach, reported safety…
- ENHANCE-ITIndependent statistical analysis of Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving: Complete Statistical AnalysisIndependent statistical analysis of Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01822587).
- Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Enzastaurin for Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enzastaurin for Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00192114).
- Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- EPICIndependent statistical analysis of Mechanisms of EPO-induced Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03810911).
- EPIC-SRIndependent statistical analysis of EPIC-SR (NCT05011513), the randomized, placebo-controlled phase 2/3 trial of nirmatrelvir plus ritonavir in standard-risk COVID-19, covering the log-rank primary analysis, logistic-regression odds ratios, negative binomial modelling and serious…
- Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EPITHETIndependent statistical analysis of the EPITHET phase 2 trial evaluating alteplase t-PA in acute stroke, including design, endpoints, planned methodology, and statistical interpretation.
- EPOCHIndependent statistical analysis of An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon: Complete Statistical AnalysisIndependent statistical analysis of Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ERA-PAHIndependent statistical analysis of Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02911844).
- ERECTIndependent statistical analysis of Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970502).
- Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05289830).
- Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery: Complete Statistical AnalysisIndependent statistical analysis of ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05257941).
- ESTRELLAIndependent statistical analysis of A Study of Belcesiran in Patients With AATLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04764448).
- Estrogen for Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Estrogen for Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01083641).
- ET-01 in Subjects With Lateral Canthal Lines: Complete Statistical AnalysisIndependent statistical analysis of ET-01 in Subjects With Lateral Canthal Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03326856).
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Etirinotecan Pegol (NKTR-102) in NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Etirinotecan Pegol (NKTR-102) in NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01773109).
- Etoposide in Patients With COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Etoposide in Patients With COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04356690).
- Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: Complete Statistical AnalysisIndependent statistical analysis of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EVACELIndependent statistical analysis of Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01678664).
- EVADEComplete statistical analysis of the randomized phase 2/3 EVADE trial of ADG20 for the prevention of COVID-19, including trial design, primary and secondary endpoints, risk differences, hazard ratios, statistical methodology, safety, and…
- Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression: Complete Statistical AnalysisIndependent statistical analysis of Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria: Complete Statistical AnalysisIndependent statistical analysis of Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02982720).
- Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA: primary endpoint results, effect estimate with confidence interval, sample-size…
- Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…